A retrospective study to determine impact of high fasting plasma glucose in clinical outcome of patients with advanced NSCLC treated with frontline pembrolizumab
Latest Information Update: 19 Nov 2021
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Nov 2021 New trial record
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress